Box

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Chen W. Liaw, Derek T. Chalmers, Dominic P. Behan, Dominique Maciejewski-Lenior, James N. Leonard, I-Lin Lin, and Daniel Ortuno

Serial No.: Not yet assigned

Group Art Unit: Not yet assigned

Filing Date: Herewith

Examiner: Not yet assigned

For: ENDOGENOUS AND NON-ENDOGENOUS VERSIONS OF HUMAN G

PROTEIN-COUPLED RECEPTORS

Patent Application

EXPRESS MAIL LABEL NO: EL884785038 US DATE OF DEPOSIT: February 26, 2002

ELBB4785038US

	Sequence Design
	t Commissioner for Patents eton, DC 20231
Sir:	
	PATENT APPLICATION TRANSMITTAL LETTER
5	Transmitted herewith for filing, please find
	A Utility Patent Application under 37 C.F.R. 1.53(b).
	It is a continuing application, as follows:
	☐ continuation ☐ divisional ☐ continuation-in-part of prior application number/
	A Design Patent Application (submitted in duplicate).
	Request for Nonpublication is attached.

DOCKET NO.	:	AREN-0320
------------	---	------------------

- 2 -

PATENT

Including the following:

New o	or Revised Specification, including pages 1 to 84 containing:				
\boxtimes	Specification				
\boxtimes	Claims				
\boxtimes	Abstract				
	Substitute Specification, including Claims and Abstract.				
	The present application is a continuation application of Application No filed The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Since none of those amendments incorporate new matter into the parent application, the present revised Specification also does not include new matter.				
	The present application is a continuation application of Application No filed, which in turn is a continuation-in-part of Application No filed The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Although the amendments in the parent C-I-P application may have incorporated new matter, since those are the only revisions included in the present application, the present application includes no new matter in relation to the parent application.				
A copy of earlier application Serial No, including Specification, Claims and Abstract (pages 1 - @@), to which no new matter has been added TOGETHER WITH a copy of the executed oath or declaration for such earlier application and all drawings and appendices. Such earlier application is hereby incorporated into the present application by reference.					
to Re	e enter the following amendment to the Specification under the Cross-Reference lated Applications section (or create such a section): "This Application: a continuation of \square is a divisional of \square claims benefit of U.S. provisional cation Serial No				

	DOCKET NO.: AREN-0320 -3-						
		Signed Statement attached deleting inventor(s) named in the prior application.					
		A Preliminary Amendment.					
	×	21 Sheets of Formal Drawings.					
		Drawing view to publish:1					
		Petition to Accept Photographic Drawings.					
		☐ Petition Fee					
-	\boxtimes	An ☐ Executed ☑ Unexecuted Declaration or Oath and Power of Attorney.					
		An Associate Power of Attorney.					
		An Executed Copy of Executed Assignment of the Invention to					
-		□ A Recordation Form Cover Sheet. □ Recordation Fee - \$40.00. The prior application is assigned of record to Priority is claimed under 35 U.S.C. § 119 of Patent Application No filed in (country). □ A Certified Copy of each of the above applications for which priority is					
		claimed: is enclosed.					

has been filed in prior application Serial No. _____ filed _____.

in English."

Please enter the following amendment to the first sentence of the specification (or create such a sentence): "This application claims benefit of international application No. _____, which was published under PCT Article 21(2)

specification.

Information Disclosure Statement.

enclosed herewith.

Attached Form 1449.

DOCKET NO.: AREN-0320 -4- PATEN						
×	Applicant(s) by its/their undersigned attorney, claims small entity status under 37 C.F.R. §1.27 as:					
	an Independent Inventor					
	☑ a Small Business Concern					
	a Nonprofit Organization.					
\boxtimes	Diskette Containing DNA/Amino Acid Sequence Information.					
\boxtimes	Statement to Support Submission of DNA/Amino Acid Sequence Information.					
\boxtimes	Sequence listing consisting of pages 1-97.					
	The computer readable form in this application, is identical with that filed in Application Serial Number, filed In accordance with 37 CFR 1.821(e), please use the \square first-filed, \square last-filed or \square only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is \square included in the originally-filed specification of the instant application,					

included in a separately filed preliminary amendment for incorporation into the

Copies of each of the references listed on the attached Form PTO-1449 are

Appended Material as follows:

A copy of Petition for Extension of Time as filed in the prior case.

 \boxtimes

The foregoing amount due.

claims under 37 C.F.R. 1.16.

DOCE	ŒT NO). : AREN-0	320	- 5 -			PA
\boxtimes	Return Receipt Postcard (should be specifically itemized).						
	Other a	as follows: _					
FEE C	ALCUL	ATION:					
	calcula		ig fee. (At le			of the prior app ident claim mu	
				SMAL	L ENTITY	NOT SM	ALL ENTIT
				RATE	FEE	RATE	FE
DESIGN	N APPLIC	ATION		\$165.00	\$	\$330.00	\$
UTILIT	Y APPLIC	CATIONS BASE	FEE	\$370.00	\$370	\$740.00	s
CALCU		CATION; ALL C AFTER ENTRY					
	****	No. Filed	No. Extra	******			
	TAL AIMS	36- 20 =	16	\$9 each	\$144	\$18 each	\$
	DEP. AIMS	18-3=	15	\$42 each	\$630	\$84 each	\$
		ENTATION OF T CLAIM	MULTIPLE	\$140	\$	\$280	\$
ADDITIONAL FILING FEE			*******	\$774		s	
TOTAL	FILING I	FEE DUE		<u> </u>	\$1144		\$ \$
		ck is enclose		-	-	the following fo	ees and t
	refund	any overpay	ment associ	ated with th	is communic	cation or during eet is provided	g the pend

Any additional filing fees required, including fees for the presentation of extra

Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).

The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: February 26, 2002

Michael P. Straher Registration No. 38,325

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

©2001 WW

DOCKET NO.: AREN-0320 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:			
Liaw et al.			
Serial No.: Not Assigned	Group Art Unit: Not Assigned		
Filing Date: Herwith	Examiner: Not Assigned		
For: Endogenous and Non-Endogenous Receptors	Versions of Human G Protein-Coupled		
U. S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, Virginia 22202	Express Mail #EL884785038US		

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

\bowtie	I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the
	contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
	I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
	I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

DOCK	ET NO.: AREN-0320	-2-	PATENT
	•	copy of the computer readable form,), contains identical data to that origin	
Date:	February 26, 2002	Michael P. Straher Registration No. 38,325	

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2001 WW